A global team of industry specialists can help life sciences companies map out risk management strategies and tactics as new issues — and opportunities — emerge.
Serving 34 of top 50 pharma firms…seven of top 10 generics…35 of top 50 medical device makers…19 of top 50 biotechs
The 45-minute, complimentary webcast will explain how the insurance industry is responding to the Food and Drug Administration’s (FDA) proposed labeling changes and to the emergence of biosimilar products.
Drug development and marketing. Pricing challenges amid health care reform. Breakthrough health discoveries and “fast track” approvals. The continuing growth of generics and emerging biosimilars. A complex and evolving global regulatory environment. Amid this dynamic and ever-changing business climate, Marsh’s life sciences industry experts develop and implement strategies tailored to your unique needs.
Among our areas of specialty:
By helping reduce your total cost of risk with tailored solutions — insurance brokerage, advisory, and risk management services — Marsh can help you minimize the volatility and severity of risk, protect assets, and maintain profitability.
For clients across the global pharmaceutical industry — biopharma, specialty drugs, generics, animal health, and nutraceuticals — Marsh offers solutions that include:
For clients across the global biotech industry — from large global enterprises to small specialty and “incubator” firms — Marsh offers solutions that include:
For medical device manufacturers, diagnostics companies, and consumer health aid product marketers, Marsh offers solutions that include:
For life sciences service providers — wholesale distributors, research institutes, contract manufacturers (CMOs), and contract developers (CDMOs) — Marsh offers solutions that encompass: